Researchers have harnessed artificial intelligence and deep learning to advance genome editing and drug discovery. The University of Zurich unveiled 'Pythia', an AI model that predicts double-stranded DNA repair outcomes, enhancing CRISPR precision and safety. Separately, KAIST developed an AI model, BInD, capable of autonomously designing optimized drug candidates targeting complex cancer mutations. Meanwhile, Monash University researchers engineered nanobody-antibody conjugates to improve mRNA-LNP targeted delivery, enhancing therapeutic efficacy with laser precision. Collectively, these breakthroughs demonstrate AI’s expanding role in tailoring gene editing and accelerating precision drug development.